Axitinib

For research use only.

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

68 publications

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 64 In stock
USD 70 In stock
USD 120 In stock
USD 217 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Axitinib has been cited by 68 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M3vDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S5XmlEPTB;MD6wNFAxPTF|IN88US=> Ml;0V2FPT0WU
NCI-H1703 NGTsRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\ad5RWUUN3ME2wMlAxODlyMjFOwG0> MV\TRW5ITVJ?
KASUMI-1 M1\UeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEC2PFIh|ryP NGKwW|NUSU6JRWK=
CGTH-W-1 M3PZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEC3NlIh|ryP MoP3V2FPT0WU
A204 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7IW3RKSzVyPUCuNFA6QTJizszN MmH0V2FPT0WU
HOP-62 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMUC4N|Yh|ryP MknEV2FPT0WU
H-EMC-SS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUGwNFUh|ryP MoXVV2FPT0WU
KU812 NYPkSXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fOUmlEPTB;MD6xOlU4PyEQvF2= M3TJbXNCVkeHUh?=
EM-2 NUH2SFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rvZWlEPTB;MD6xOlgyPiEQvF2= MWXTRW5ITVJ?
LAMA-84 M{iyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfpbldKSzVyPUCuNVc3PjVizszN M2XienNCVkeHUh?=
JAR NELUWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7CV4ZKSzVyPUCuNlM6QDlizszN MWfTRW5ITVJ?
G-361 NXPYXoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XlU2lEPTB;MD6zNlMzPSEQvF2= MUfTRW5ITVJ?
KG-1 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKwO2hKSzVyPUCuN|c3PDJizszN NFjoS|BUSU6JRWK=
BV-173 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwM{mzNkDPxE1? M1jQVnNCVkeHUh?=
K5 NW\GNWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P5NGlEPTB;MD60NlEzPyEQvF2= MnnYV2FPT0WU
MEG-01 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTSTWM2OD1yLkSyN|YyKM7:TR?= M1f6WnNCVkeHUh?=
MFM-223 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\6TWM2OD1yLkS0O|c3KM7:TR?= NFfaXXFUSU6JRWK=
BE-13 NGW2[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIRWlEPTB;MD61NVAxQCEQvF2= NU\iWWRXW0GQR1XS
NEC8 NHvnZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr0TWM2OD1yLkeyNVE{KM7:TR?= MX;TRW5ITVJ?
SW756 NXvEUGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrtWYVmUUN3ME2wMlk6QDR4IN88US=> M1TrOnNCVkeHUh?=
A2780 NYqyc45TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjqOpFwUUN3ME2xMlAyOTR4IN88US=> MoroV2FPT0WU
NB14 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHpTWM2OD1zLkCxPFAyKM7:TR?= M3\lSnNCVkeHUh?=
H4 NXrEeWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwME[0NlIh|ryP M2fRRnNCVkeHUh?=
SK-OV-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDy[mVjUUN3ME2xMlA3PjN|IN88US=> M4fwN3NCVkeHUh?=
AN3-CA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rDe2lEPTB;MT6wPFM5QSEQvF2= MVXTRW5ITVJ?
A427 NYq2UJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;sTHJMUUN3ME2xMlExOzhzIN88US=> NIPjVlhUSU6JRWK=
ES7 M36wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvQbI9tUUN3ME2xMlEyOzN2IN88US=> NGLKOZNUSU6JRWK=
AGS NIX5dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3pSXJXUUN3ME2xMlEyOzl3IN88US=> NE\wbnJUSU6JRWK=
G-402 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi1TWM2OD1zLkG0Olk1KM7:TR?= NEK4ZVlUSU6JRWK=
ES5 M2m2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7qOJFwUUN3ME2xMlE4OjR6IN88US=> MkfrV2FPT0WU
DEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;1cmpKSzVyPUGuNlU1PTdizszN MUXTRW5ITVJ?
NB10 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK4cY1KSzVyPUGuN|I2PTdizszN M{LGNXNCVkeHUh?=
NCI-H1581 M3vCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwM{mwOFIh|ryP MWDTRW5ITVJ?
D-566MG MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwNEC2PFMh|ryP NHnDU2FUSU6JRWK=
LXF-289 NWfYfIh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDRe3RKSzVyPUGuOFM6QTZizszN M1u2VHNCVkeHUh?=
BT-549 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHMRmdKSzVyPUGuOVY6ODlizszN NXfQPI1lW0GQR1XS
NKM-1 M3TFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LZUmlEPTB;MT62NFU2PiEQvF2= NGjqXHBUSU6JRWK=
SW780 NGTpVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335e2lEPTB;MT62OVE2QCEQvF2= MUXTRW5ITVJ?
NCI-H292 NG\4VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HVdGlEPTB;MT62OlM5OyEQvF2= NUC4cWd[W0GQR1XS
HMV-II NHzFTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwN{C0PFgh|ryP Ml\UV2FPT0WU
ALL-PO NEPC[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXTYZKSzVyPUGuPFAxOTVizszN NGX6OFNUSU6JRWK=
UACC-257 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33pc2lEPTB;MT64NlE3OyEQvF2= NYLOeGltW0GQR1XS
PA-1 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwOEK3NlUh|ryP NVntSpBiW0GQR1XS
HD-MY-Z NHzzW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWruTWZXUUN3ME2xMlg3OjhzIN88US=> MoTQV2FPT0WU
HSC-4 M2\FZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjtUnBKSzVyPUGuPVM5OzlizszN NHPyXmpUSU6JRWK=
GCT NXHrXG4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\pdHNKSzVyPUKuNFA6OTZizszN MUPTRW5ITVJ?
RT-112 NGnrZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwMUO0NlQh|ryP MXXTRW5ITVJ?
A172 M3;2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJwMUO2NFYh|ryP MVXTRW5ITVJ?
HCE-T NYHSVIFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwMkC1PVgh|ryP Mn;XV2FPT0WU
YH-13 NGXSOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTWTWM2OD1{LkKxOlcyKM7:TR?= MX3TRW5ITVJ?
DK-MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXZlNTUUN3ME2yMlI{QDN2IN88US=> MVTTRW5ITVJ?
ACN M{nqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwMkO4O|Uh|ryP NF30SI9USU6JRWK=
VA-ES-BJ M4fPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMkS5OVch|ryP MYjTRW5ITVJ?
L-363 M1nm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvtTWM2OD1{LkK4NFYyKM7:TR?= NHjTVldUSU6JRWK=
HuH-7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwNEKxOlUh|ryP MkLWV2FPT0WU
A4-Fuk NV34U2trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwNEexOlgh|ryP M1GzbnNCVkeHUh?=
T-24 M2T3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDVTWM2OD1{LkS4NFM4KM7:TR?= NFTMdYxUSU6JRWK=
GOTO M4DJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fCfmlEPTB;Mj61N|AyOyEQvF2= MYLTRW5ITVJ?
MV-4-11 M1zuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjXZlNDUUN3ME2yMlU6OTZ7IN88US=> M2HNUnNCVkeHUh?=
DMS-114 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP6[YFWUUN3ME2yMlY3OzR3IN88US=> MnTvV2FPT0WU
MHH-NB-11 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:xcmNTUUN3ME2yMlcxOjl7IN88US=> MWnTRW5ITVJ?
CHP-212 NWHHPXZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOEKwPVEh|ryP NUfQNYUyW0GQR1XS
DMS-273 M3zNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6SlRZUUN3ME2yMlkxOjB5IN88US=> NHK5RZFUSU6JRWK=
SF295 NHnOTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwMEK1PVch|ryP NHW2[XpUSU6JRWK=
NCI-H1563 NWXoOmVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXKR|lKSzVyPUOuNVUxODVizszN MoroV2FPT0WU
NCI-H446 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwMkK4NFUh|ryP NILNTJdUSU6JRWK=
HCC1806 NGrCfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n5VWlEPTB;Mz6yO|Y2PyEQvF2= NUjhXXF2W0GQR1XS
SF126 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTNwM{CwNVch|ryP NF\1b49USU6JRWK=
SW982 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwM{O4O|Uh|ryP NUW0Voh7W0GQR1XS
ES8 NULFdYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNwM{S5PVkh|ryP M{TheXNCVkeHUh?=
SCC-4 M{jJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwNUCzPVYh|ryP NIKwUIpUSU6JRWK=
RPMI-8226 M4XnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvud3EyUUN3ME2zMlYzPjF4IN88US=> MWrTRW5ITVJ?
EW-11 NUXmb|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M363cWlEPTB;Mz62N|AzOiEQvF2= Ml3KV2FPT0WU
COR-L105 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV20[XFXUUN3ME2zMlY{OzN2IN88US=> NGLuS5lUSU6JRWK=
ES1 NYrBe2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXwPZpKSzVyPUOuPFMxQTRizszN M2rnTHNCVkeHUh?=
KMOE-2 NUjlRW9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmryTWM2OD1|LkmxPFA5KM7:TR?= NVHZdWUxW0GQR1XS
ABC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;UTWM2OD1|LkmzPVEyKM7:TR?= M4fK[nNCVkeHUh?=
NCI-H526 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LnZmlEPTB;Mz65PVEzPiEQvF2= MXvTRW5ITVJ?
HCC1395 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnBZ5ZKSzVyPUOuPVk1QDRizszN M4TCZ3NCVkeHUh?=
DU-145 NFHnNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfSWplKSzVyPUSuNVI5OjVizszN M2jCU3NCVkeHUh?=
JEG-3 M2PDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33zXmlEPTB;ND6xOVkyPiEQvF2= NYewcFV4W0GQR1XS
HCC1187 NIXTVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLmcJFNUUN3ME20MlIyPTl5IN88US=> NHyyVGxUSU6JRWK=
LC-2-ad MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LHSGlEPTB;ND6yNlE4PyEQvF2= MkHQV2FPT0WU
ONS-76 M3q3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwMkSxPVIh|ryP NXfRUGUxW0GQR1XS
CAL-27 NYLaVY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwMkSzOFQh|ryP NH;qZolUSU6JRWK=
8-MG-BA MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr1RoNKSzVyPUSuNlY3PThizszN MoWyV2FPT0WU
HGC-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz1TWM2OD12LkK5OlYh|ryP MmmwV2FPT0WU
Hs-578-T MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLtRVFtUUN3ME20MlMyPDZ6IN88US=> MWjTRW5ITVJ?
EW-1 M4LSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwNUOwNVQh|ryP NYDmeVdNW0GQR1XS
SW1573 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwNUWxOlMh|ryP Mn;4V2FPT0WU
SNU-423 M4XuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[xd2lEPTB;ND62NFc6KM7:TR?= MXTTRW5ITVJ?
HOS NEHLR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW5TWM2OD12Lk[5O|ch|ryP M{DibXNCVkeHUh?=
LB1047-RCC NE\GRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjSTWJNUUN3ME20MlgyPDF6IN88US=> M4GzcHNCVkeHUh?=
ChaGo-K-1 NUTpN5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\wNnhzUUN3ME20Mlg6ODR6IN88US=> M4fOXnNCVkeHUh?=
A3-KAW M2Lv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;Bc5BKSzVyPUSuPVc{PTJizszN MnjoV2FPT0WU
CAS-1 NEfSfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TBZmlEPTB;ND65PVkxQCEQvF2= NYHPcolmW0GQR1XS
NBsusSR NXeyWHduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fTO2lEPTB;NT6wN|UyPCEQvF2= MofuV2FPT0WU
KM12 NXniPYdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TsbGlEPTB;NT6yPVgzPyEQvF2= MUHTRW5ITVJ?
NCI-H1155 NGTufmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\BPWlEPTB;NT6zPFE5PSEQvF2= MmLJV2FPT0WU
EFM-19 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG2XIpMUUN3ME21MlQyPzN5IN88US=> MnfHV2FPT0WU
D-392MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwNUe4OFkh|ryP MlLLV2FPT0WU
JVM-3 M{TNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP1OGVYUUN3ME21MlczOzJ3IN88US=> MXTTRW5ITVJ?
EW-16 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DJNGlEPTB;NT63OVU5OyEQvF2= MWPTRW5ITVJ?
KARPAS-45 M3Hjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTVwOESzNlUh|ryP MX3TRW5ITVJ?
NCI-H28 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfqWW8zUUN3ME21Mlg4QTF6IN88US=> NIW1R2VUSU6JRWK=
COLO-829 NWTXW2trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTVwOUG1NFQh|ryP NXrZUJRbW0GQR1XS
KM-H2 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQVY9KSzVyPUWuPVI{QTVizszN MXzTRW5ITVJ?
NCI-H82 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXPV3NYUUN3ME21MlkzPzdzIN88US=> M1G3THNCVkeHUh?=
OAW-42 M2HLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\TcmlEPTB;NT65PFgzOSEQvF2= MorxV2FPT0WU
A704 M{js[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZwMUC1O|Qh|ryP NIXZc2NUSU6JRWK=
NCI-H1048 NULtOWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XKV2lEPTB;Nj6xNFU6QSEQvF2= M2PkVHNCVkeHUh?=
LOXIMVI M1;hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fpU2lEPTB;Nj6xNVI1QCEQvF2= NVmyXoltW0GQR1XS
MKN45 NF;rTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknYTWM2OD14LkK2NFE3KM7:TR?= M{HJUXNCVkeHUh?=
D-502MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwMki4OVch|ryP MV;TRW5ITVJ?
HUTU-80 NIrXPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j4V2lEPTB;Nj60NVY5QCEQvF2= MUnTRW5ITVJ?
S-117 NX2wWHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXCTWM2OD14LkWwNlY4KM7:TR?= NIC5VGdUSU6JRWK=
HCC1569 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;JcIpEUUN3ME22MlU{PzN5IN88US=> M1vFTnNCVkeHUh?=
J-RT3-T3-5 M1T0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXFbVZZUUN3ME22MlU1PTd{IN88US=> M3i1Z3NCVkeHUh?=
OC-314 NG\qO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHoZmpHUUN3ME22MlkyOTV7IN88US=> MXLTRW5ITVJ?
SNU-449 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ITWM2OD15LkCxNFczKM7:TR?= MVrTRW5ITVJ?
NCI-H720 NYLJToxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTdwMUmzOFUh|ryP NGPKepJUSU6JRWK=
KP-N-YS MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrtTWM2OD15LkKwO|Ih|ryP MmfZV2FPT0WU
IGROV-1 NGPCS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfJWZFjUUN3ME23MlMzOzh4IN88US=> NXfEcmNSW0GQR1XS
SK-PN-DW MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTdwNEixOUDPxE1? MlPwV2FPT0WU
HCC1419 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnUOGNKSzVyPUeuOVMh|ryP NHLUdVNUSU6JRWK=
HAL-01 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXCTWM2OD15Lk[wOlQ1KM7:TR?= Mn3nV2FPT0WU
HCC2998 NVryPXlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnQdYZKSzVyPUeuOlA4PDNizszN NEO2dlFUSU6JRWK=
SK-N-FI NV[0SVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLzeoRKSzVyPUeuOlMxOzNizszN NVHLfWVjW0GQR1XS
GI-ME-N MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PLOGlEPTB;Nz62OFk{PCEQvF2= Mn3wV2FPT0WU
SW1088 NUDyR|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\MUGtKSzVyPUeuOlU5OjZizszN MYrTRW5ITVJ?
IA-LM NGfjWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTdwNki2NVMh|ryP MY\TRW5ITVJ?
SK-NEP-1 M33z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTCe3RlUUN3ME23MlY6PjFizszN MXrTRW5ITVJ?
MDA-MB-415 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXWeFFUUUN3ME23Mlg6OTh4IN88US=> MoC0V2FPT0WU
COLO-800 NF\XVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTdwOUS0PVIh|ryP Ml7UV2FPT0WU
NCI-H2228 NFHUZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml36TWM2OD16LkG1O|g{KM7:TR?= M{PYZ3NCVkeHUh?=
D-423MG M1\yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TwN2lEPTB;OD6yNVczKM7:TR?= NVG2SG1iW0GQR1XS
TE-1 NUX2c|lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G0WGlEPTB;OD60OFMyPiEQvF2= NG\3d5BUSU6JRWK=
NOS-1 NYHoPWRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThwNUG1N|Qh|ryP NHzFSmZUSU6JRWK=
8505C Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSxdFJyUUN3ME24MlY1QDJ2IN88US=> MXTTRW5ITVJ?
HEC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPrTW9rUUN3ME24Mlc5PDN7IN88US=> MYTTRW5ITVJ?
TE-11 NHfYdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLqTWM2OD16Lkm5OVUyKM7:TR?= MoXpV2FPT0WU
CTB-1 M1jJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTkNmF6UUN3ME25MlAyPDN|IN88US=> MWXTRW5ITVJ?
TGBC11TKB M1y0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH6TWM2OD17LkCyNlQyKM7:TR?= MmfaV2FPT0WU
NB17 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmizTWM2OD17LkG4PFch|ryP MknxV2FPT0WU
Becker MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvRbJJKSzVyPUmuOFE6PDRizszN NFLqcGJUSU6JRWK=
SN12C NI\jTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMTWM2OD17LkS1NlM1KM7:TR?= MXLTRW5ITVJ?
COLO-320-HSR M{DKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\HTWM2OD17Lk[wNlM4KM7:TR?= MWjTRW5ITVJ?
D-283MED NUDiZWI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHpdFk2UUN3ME25MlY{ODd{IN88US=> Mm[zV2FPT0WU
D-263MG M3Txemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HXTWlEPTB;OT64N|M5PCEQvF2= MXrTRW5ITVJ?
MEL-JUSO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwOUCxNlch|ryP NIPCVZZUSU6JRWK=
T98G MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPLTWM2OD17LkmwNlA{KM7:TR?= NWDWdXRuW0GQR1XS
HLE NFzQW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj2TWM2OD17LkmwPVA6KM7:TR?= NGq1OYlUSU6JRWK=
Ca9-22 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvSfWtCUUN3ME2xNE4xPjZ3IN88US=> MXjTRW5ITVJ?
OS-RC-2 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULHZYl[UUN3ME2xNE4yODR3IN88US=> NGi1flhUSU6JRWK=
T47D M1\ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFcHdVUUN3ME2xNE4yPTVizszN Ml7oV2FPT0WU
GI-1 NIfiZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrCS4h3UUN3ME2xNE4{PTN|IN88US=> M{[4UHNCVkeHUh?=
NUGC-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFyLkS0NFIh|ryP MnznV2FPT0WU
MDA-MB-361 NXiwS3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHnU4ZpUUN3ME2xNE41PDN{IN88US=> MXnTRW5ITVJ?
SCC-15 M{LuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;wTWM2OD1zMD60O|E5KM7:TR?= NXz0PFB2W0GQR1XS
KS-1 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj2NZhIUUN3ME2xNE43OzBzIN88US=> MX3TRW5ITVJ?
CAL-12T MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZb3NKSzVyPUGwMlY{PjFizszN Mk\xV2FPT0WU
OVCAR-4 NWOwRm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PSdWlEPTB;MUCuO|A3QCEQvF2= NILR[GtUSU6JRWK=
HuP-T4 M4myVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFzLkCzNlgh|ryP NULMSo5[W0GQR1XS
NCI-H358 M4PFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFzLkK2OVch|ryP NYDveIpnW0GQR1XS
HO-1-N-1 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3jUYJKSzVyPUGxMlM{QThizszN M4XIVHNCVkeHUh?=
NH-12 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\v[2lEPTB;MUGuOVM4QCEQvF2= NEf4NWNUSU6JRWK=
MOLT-4 NVnOdnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrvV5dKUUN3ME2xNU42QTh3IN88US=> M3PEW3NCVkeHUh?=
K-562 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzLkeyOFgh|ryP MkfmV2FPT0WU
ES6 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M164dWlEPTB;MUGuPFU5OSEQvF2= MYfTRW5ITVJ?
RO82-W-1 NULhW5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq5fG9KSzVyPUGxMlkxPjRizszN NUfMcnlUW0GQR1XS
Ramos-2G6-4C10 NXP0d4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4TGtnUUN3ME2xNU46OzJizszN NX;LfJQ4W0GQR1XS
23132-87 M4rieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nvNmlEPTB;MUKuNFgzOSEQvF2= NFrHPGhUSU6JRWK=
A549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnmUoZvUUN3ME2xNk4{Ojh3IN88US=> NUC0T5MyW0GQR1XS
NCI-H23 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTNTWM2OD1zMj61NFI3KM7:TR?= MVXTRW5ITVJ?
H9 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrCO4FQUUN3ME2xNk42PTd5IN88US=> M1jlOnNCVkeHUh?=
LB771-HNC NXLDWZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\l[oxKSzVyPUGyMlc3PSEQvF2= M2P2PXNCVkeHUh?=
QIMR-WIL M2PzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLzcZNKSzVyPUGyMlgzPThizszN MmriV2FPT0WU
HSC-3 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fpUmlEPTB;MUKuPVI4PiEQvF2= MoTmV2FPT0WU
PFSK-1 NVzwWFJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljBTWM2OD1zMj65OVA4KM7:TR?= M4PyenNCVkeHUh?=
ETK-1 NXvCcYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ORY42UUN3ME2xN{4xPzd7IN88US=> MnP5V2FPT0WU
SW1710 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4PWlEPTB;MUOuN|Y1OSEQvF2= NFT4RXJUSU6JRWK=
COLO-684 M3fJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF|LkS1OFEh|ryP MljyV2FPT0WU
RPMI-7951 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjWSItKSzVyPUGzMlUyOzZizszN M3PWOXNCVkeHUh?=
A101D NFzrNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmzbmJKSzVyPUGzMlU{PDlizszN NGTBOHdUSU6JRWK=
KE-37 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF|LkW4PFch|ryP MojvV2FPT0WU
SiHa MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfa[2hKSzVyPUGzMlg{PDZizszN MXvTRW5ITVJ?
NCI-H226 NHXNR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKyZlFxUUN3ME2xN{45QDB6IN88US=> NF3KVplUSU6JRWK=
DB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF|Lkm5Nlgh|ryP M1:1UHNCVkeHUh?=
HT-1197 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF2LkC4NFkh|ryP NVz3e49mW0GQR1XS
SBC-5 NXLnZY5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF2LkGzOlIh|ryP MVzTRW5ITVJ?
VMRC-RCZ M1TSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfMelNKSzVyPUG0MlU4PzRizszN MkHKV2FPT0WU
697 NWL6VppsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrmcohKSzVyPUG0MlYzPyEQvF2= MUXTRW5ITVJ?
OMC-1 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF2Lke4PFgh|ryP NGnpRY9USU6JRWK=
SKG-IIIa NV33cYE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\kOllSUUN3ME2xOE45ODBzIN88US=> M2H5cHNCVkeHUh?=
DOK Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\BXlhKSzVyPUG0Mlk6OzNizszN NWCwe5Z3W0GQR1XS
NCI-H2029 NFrJWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe4TWM2OD1zNT6zOlAzKM7:TR?= NVviVnEyW0GQR1XS
NCI-H2009 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XVb2lEPTB;MUWuOVA6PSEQvF2= MnXCV2FPT0WU
LK-2 NVfUWY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvOTWM2OD1zNT62OFQ6KM7:TR?= MX7TRW5ITVJ?
NCI-H661 NUTrOZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ntXmlEPTB;MUWuPVA4PSEQvF2= MnP3V2FPT0WU
GT3TKB NYTJWYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;STWM2OD1zNj6wOlc3KM7:TR?= MoXYV2FPT0WU
GP5d NF\JT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF4LkO0NkDPxE1? M4K2O3NCVkeHUh?=
SK-MEL-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF4LkS0PFUh|ryP MnLxV2FPT0WU
SK-UT-1 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O1XGlEPTB;MU[uOVY2KM7:TR?= MYTTRW5ITVJ?
NB7 M3rNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDBXlZKSzVyPUG2MlY6PzFizszN M4LSOXNCVkeHUh?=
NCI-H460 NEDtWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT4TWM2OD1zNj63N|I3KM7:TR?= NFO2[GVUSU6JRWK=
8305C M4rNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLNTWM2OD1zNj63PFc4KM7:TR?= MV;TRW5ITVJ?
CaR-1 NVPKU5FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e5[mlEPTB;MU[uPFEyOSEQvF2= NVzOSVVJW0GQR1XS
D-247MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF4Lki2NlUh|ryP Ml7oV2FPT0WU
LoVo NGTHT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF4Lkm0PFgh|ryP NEPTd2tUSU6JRWK=
NCI-H2405 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfOWVhKSzVyPUG3MlE6ODhizszN NFrz[|ZUSU6JRWK=
AU565 NHTmNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTYUpJ7UUN3ME2xO{4zOjVizszN M1TxZ3NCVkeHUh?=
OCI-AML2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu3TWM2OD1zNz61N|E4KM7:TR?= M1HaUXNCVkeHUh?=
22RV1 NXra[ZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGxTWM2OD1zNz61PFg1KM7:TR?= NXPmU5ozW0GQR1XS
HT-144 M{nWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5Lk[1PVgh|ryP MoCxV2FPT0WU
HuO9 M3nofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF5LkewN|Eh|ryP MVrTRW5ITVJ?
Daoy M3vZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF5LkexPFQh|ryP MUnTRW5ITVJ?
SJRH30 NGLPe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HRemlEPTB;MUeuPFQ5QSEQvF2= MnnFV2FPT0WU
CHL-1 NVr0SHRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF5LkmyOFkh|ryP NWSzT|lSW0GQR1XS
J82 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz3WY9mUUN3ME2xO{46PjN3IN88US=> NIrDb|FUSU6JRWK=
COR-L23 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHqTWM2OD1zOD6wNFEyKM7:TR?= M{\TUnNCVkeHUh?=
SNU-C2B MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF6LkKyO|Yh|ryP NVTnO3p7W0GQR1XS
NCI-H1770 NV3TXIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXns[JV7UUN3ME2xPE41PjF3IN88US=> NInqUZhUSU6JRWK=
MHH-PREB-1 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;RemlEPTB;MUiuOVY6PyEQvF2= Mk\XV2FPT0WU
ES3 M4C1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV64OoJPUUN3ME2xPE42QDh|IN88US=> NIPYemJUSU6JRWK=
MDA-MB-231 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD1zOD62OVAzKM7:TR?= M3XXSnNCVkeHUh?=
MN-60 NUfmNpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn3[4xKSzVyPUG5MlA2QTJizszN NWHI[2JDW0GQR1XS
EPLC-272H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF7LkO3NFgh|ryP NITr[HNUSU6JRWK=
SW948 NFTodZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnPUFBEUUN3ME2xPU4{QTN2IN88US=> NFfF[XRUSU6JRWK=
MOLT-13 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF7LkS1OFYh|ryP MVfTRW5ITVJ?
HL-60 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rETGlEPTB;MkCuNlE1OSEQvF2= M4XXRnNCVkeHUh?=
CP50-MEL-B NXiwRlF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\3c21wUUN3ME2yNE41PzR6IN88US=> MYPTRW5ITVJ?
NTERA-S-cl-D1 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ON2lEPTB;MkCuOFk4QCEQvF2= NWLrWnA{W0GQR1XS
KINGS-1 NU\oU5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfYb4doUUN3ME2yNE44QTZ5IN88US=> Mn3qV2FPT0WU
DOHH-2 M1\uVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULKbFloUUN3ME2yNE46ODZizszN MX\TRW5ITVJ?
BB65-RCC NV;NZnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITGb2tKSzVyPUKwMlkzQDVizszN MV3TRW5ITVJ?
NB12 M3f2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJzLkCzPVQh|ryP MXrTRW5ITVJ?
KY821 NFzXN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf3TWM2OD1{MT61PFIh|ryP NH:0Z2VUSU6JRWK=
PSN1 M1HrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJzLk[0OVMh|ryP MUHTRW5ITVJ?
EGI-1 NHvpV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17Eb2lEPTB;MkGuO|Q2PCEQvF2= MnzpV2FPT0WU
CTV-1 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ{LkOwN|Eh|ryP NGfx[HpUSU6JRWK=
TI-73 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrlTWM2OD1{Mj6zOFk5KM7:TR?= MVLTRW5ITVJ?
LCLC-103H NEfHW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nQW2lEPTB;MkKuOFc2OiEQvF2= M{PicHNCVkeHUh?=
D-542MG NGi5WFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LNd2lEPTB;MkKuOVU2QCEQvF2= M1rRSHNCVkeHUh?=
ATN-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ{Lk[0N|kh|ryP M1H0cHNCVkeHUh?=
SK-MEL-1 NWLKbldVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHYTWM2OD1{Mj64N|Y5KM7:TR?= NHnGWI1USU6JRWK=
HDLM-2 NVPBVVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfnUYRRUUN3ME2yN{4yPDd6IN88US=> NWD4c2p2W0GQR1XS
UM-UC-3 MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jTfGlEPTB;MkOuNVk1PCEQvF2= NV\SXXViW0GQR1XS
NCI-H1573 M3niPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPWTWM2OD1{Mz60OlgyKM7:TR?= MUDTRW5ITVJ?
NCI-H520 M3P2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrrSIhnUUN3ME2yN{41QTR6IN88US=> M2excnNCVkeHUh?=
ESS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ|LkiwOVkh|ryP MknBV2FPT0WU
COR-L88 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGzTWM2OD1{Mz65OFc2KM7:TR?= MmO4V2FPT0WU
TGBC24TKB MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjxTWM2OD1{ND6wN|EzKM7:TR?= MVHTRW5ITVJ?
HCC1937 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrOnB3UUN3ME2yOE4yKM7:TR?= NXzzb2lWW0GQR1XS
RS4-11 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fFVmlEPTB;MkSuNVQzKM7:TR?= MYPTRW5ITVJ?
HCC38 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XTO2lEPTB;MkSuNlM6PCEQvF2= MnvJV2FPT0WU
RPMI-2650 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPrTWM2OD1{ND62NVYzKM7:TR?= MlqwV2FPT0WU
P12-ICHIKAWA M1\q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHUTGNEUUN3ME2yOE43OjV6IN88US=> M3\XXHNCVkeHUh?=
YAPC NEXWTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;lSWlEPTB;MkSuPFIyPCEQvF2= Mn24V2FPT0WU
NB13 M3vSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHZOGtKSzVyPUK1MlI3OTFizszN NUHPTVBFW0GQR1XS
SK-N-AS MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfWT|JiUUN3ME2yOU45PTh2IN88US=> NXzxbWZRW0GQR1XS
SK-N-DZ M2WzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILBXYpKSzVyPUK2MlA1QSEQvF2= NYHXXpdSW0GQR1XS
LS-411N MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzpcJNZUUN3ME2yOk4zODN6IN88US=> M3rmO3NCVkeHUh?=
NCI-H810 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe3clZmUUN3ME2yOk4{OTF{IN88US=> NH3mZnBUSU6JRWK=
NCI-SNU-1 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfZc|QxUUN3ME2yOk42PDV2IN88US=> MX\TRW5ITVJ?
HH M1HJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VRmlEPTB;Mk[uOVUzQSEQvF2= NVLt[WljW0GQR1XS
U-2-OS M3LaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3PHVKSzVyPUK2Mlc{QDJizszN NEXZU4lUSU6JRWK=
SF539 M3XncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3mb3d6UUN3ME2yOk45ODF6IN88US=> NVXVWY05W0GQR1XS
NCI-H2052 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj3TWM2OD1{Nz6wPFYh|ryP NFT3R21USU6JRWK=
A673 NXTPeIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PxXmlEPTB;MkeuNlExOiEQvF2= MYPTRW5ITVJ?
WM-115 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\CTWM2OD1{Nz63O|Y4KM7:TR?= NVzhU|NzW0GQR1XS
SW48 NVjjUZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmiwTWM2OD1{Nz64NFA2KM7:TR?= MmLrV2FPT0WU
NOMO-1 NFTsOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TtcGlEPTB;MkeuPFU{OiEQvF2= MlHHV2FPT0WU
PC-3 MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v1SmlEPTB;MkeuPFk1OSEQvF2= Mn;NV2FPT0WU
UMC-11 M4exRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHidI5KSzVyPUK3Mlk{PDNizszN MoTEV2FPT0WU
U-118-MG NIXWWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq5bGpKSzVyPUK4MlAyOjNizszN NHnnUGRUSU6JRWK=
NCI-H2452 NEjDR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\LTWM2OD1{OD6wPFIzKM7:TR?= NWPmbWR3W0GQR1XS
CAMA-1 NIG3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS1XI5KSzVyPUK4Mlg2PjRizszN MXzTRW5ITVJ?
MC-IXC NHGzWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fwXGlEPTB;MkmuNlM3PiEQvF2= MmPmV2FPT0WU
ES4 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ7LkOxO|Ih|ryP M3;QbHNCVkeHUh?=
BHT-101 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ7LkOyNUDPxE1? M1PCNXNCVkeHUh?=
KP-4 NXnDW45GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M371ZmlEPTB;MkmuOVE3KM7:TR?= NXKyN5YyW0GQR1XS
CAL-54 M{TWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXVTXZEUUN3ME2yPU42PDR3IN88US=> MXfTRW5ITVJ?
5637 NHvwOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK5ZocyUUN3ME2yPU43PDJzIN88US=> NYfucnFiW0GQR1XS
MOLT-16 M3vHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDUTWM2OD1{OT63NlY6KM7:TR?= MYTTRW5ITVJ?
Ca-Ski MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ7Lkm0OkDPxE1? NGTGWmpUSU6JRWK=
AsPC-1 M1PzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrUTWM2OD1|MD6wNlEzKM7:TR?= NIm0SmRUSU6JRWK=
MSTO-211H M{ewd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPwe5JKSzVyPUOwMlE2KM7:TR?= MYrTRW5ITVJ?
L-428 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DoTWlEPTB;M{CuOFA2KM7:TR?= NI\RWW1USU6JRWK=
SW1463 NUDGcVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\OUZlKSzVyPUOwMlU{QDNizszN M2XkenNCVkeHUh?=
NCI-H1648 NVK3N4hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNyLkW1O|Qh|ryP M{X0XXNCVkeHUh?=
CAKI-1 M3q5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNyLke3NFIh|ryP MnrYV2FPT0WU
YKG-1 NVf6doFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnZVnhKSzVyPUOxMlAzPjNizszN MmrPV2FPT0WU
A2058 NYq1ZnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNzLkGxOlQh|ryP Mk\hV2FPT0WU
A375 NHHYR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDYTmN{UUN3ME2zNU4yPjl4IN88US=> MWTTRW5ITVJ?
SNB75 M{fRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;sTWlEPTB;M{GuNlQ{PSEQvF2= NVflOoVMW0GQR1XS
SK-HEP-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnixTWM2OD1|MT60NlcyKM7:TR?= MW\TRW5ITVJ?
ME-180 NE\FOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNzLk[1OFIh|ryP NYnaeFdwW0GQR1XS
NCI-H209 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGzTWM2OD1|MT64NlQ4KM7:TR?= MVTTRW5ITVJ?
HC-1 NVTKe4RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEToWFFKSzVyPUOyMlE1PDZizszN MYHTRW5ITVJ?
LB373-MEL-D NH\LR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M120OWlEPTB;M{KuNVk4OSEQvF2= M13yeHNCVkeHUh?=
SNU-387 M{n4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;2c2RGUUN3ME2zNk4{OTlzIN88US=> M3PpWXNCVkeHUh?=
C32 M3PKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m5[mlEPTB;M{KuN|M2OyEQvF2= MULTRW5ITVJ?
EW-13 M1iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG4XJljUUN3ME2zNk46PDB6IN88US=> MX\TRW5ITVJ?
BFTC-905 NF20VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPtVWlHUUN3ME2zN{42OTN4IN88US=> NFzPWY1USU6JRWK=
NCI-H1299 M2TpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj5O3ZoUUN3ME2zN{42PjJzIN88US=> M3XCeHNCVkeHUh?=
LU-135 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXTTWM2OD1|Mz64NFEh|ryP M4DQNXNCVkeHUh?=
NCI-H2122 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;oTWM2OD1|Mz65PVY3KM7:TR?= MnzWV2FPT0WU
SK-LMS-1 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTN2LkSxNFch|ryP NFHoZ2pUSU6JRWK=
LNCaP-Clone-FGC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXUTlB4UUN3ME2zOE45PTF3IN88US=> NEfofVdUSU6JRWK=
NCI-H1092 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rveGlEPTB;M{WuNlc1PyEQvF2= NVTtRpZ6W0GQR1XS
MS-1 NF7rVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvDTpNHUUN3ME2zOU4{ODN6IN88US=> NFOxdlZUSU6JRWK=
KYSE-510 M1nEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fUTmlEPTB;M{WuOVA1OiEQvF2= NUi4[ZcyW0GQR1XS
NCI-H1793 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;rTWM2OD1|NT62OVQ2KM7:TR?= NWTiVWJvW0GQR1XS
MIA-PaCa-2 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\JTVg3UUN3ME2zOk4xPDl4IN88US=> M3L5d3NCVkeHUh?=
EW-22 M3vvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXRN417UUN3ME2zOk41ODd{IN88US=> NHfkZYpUSU6JRWK=
IGR-1 NXHteoNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5TWM2OD1|Nj64NVg1KM7:TR?= NFrXNGVUSU6JRWK=
HT-1080 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS0TWM2OD1|Nz6xNlUh|ryP MmXnV2FPT0WU
M14 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\vZ4NZUUN3ME2zO{4yPjR{IN88US=> MWrTRW5ITVJ?
786-0 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn1TWM2OD1|Nz6yO|k1KM7:TR?= MljTV2FPT0WU
MZ2-MEL NV:0WGx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN5LkS1NFEh|ryP MojxV2FPT0WU
NCI-H510A NEPoRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPJc4dKSzVyPUO3Mlk1OTJizszN MVHTRW5ITVJ?
LAN-6 M2[4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSyfYxXUUN3ME2zO{46PTh{IN88US=> MVPTRW5ITVJ?
SW620 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT3dnRKUUN3ME2zPE41QTd2IN88US=> NFj1[pZUSU6JRWK=
LB2241-RCC MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PC[GlEPTB;M{muPFIxPSEQvF2= M1rse3NCVkeHUh?=
Detroit562 M3XFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPGeppyUUN3ME20NE4yOjZ6IN88US=> MXzTRW5ITVJ?
HN NFT2OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRyLkG3PFIh|ryP MUXTRW5ITVJ?
HCT-15 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTKTWM2OD12MD61PVA4KM7:TR?= NYrxSWROW0GQR1XS
C2BBe1 NH[2ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;kTWM2OD12MD65NVU4KM7:TR?= NEDZW4JUSU6JRWK=
A498 NYPSTGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXDTWM2OD12MT6zNFE2KM7:TR?= Mn;RV2FPT0WU
SK-MEL-24 M{D6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXTcJFKSzVyPUSxMlQ4OjVizszN M3rue3NCVkeHUh?=
OVCAR-5 NHKxR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRzLke3Olch|ryP M1z4Z3NCVkeHUh?=
NCI-H1792 NV\MXJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXVOHo6UUN3ME20NU46QDJzIN88US=> MmT6V2FPT0WU
KOSC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHNTWM2OD12Mj6yOlk6KM7:TR?= MVnTRW5ITVJ?
Mo-T M{XNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nWbGlEPTB;NEKuPFk2QCEQvF2= MXvTRW5ITVJ?
CFPAC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHkTWM2OD12Mz60PVQ1KM7:TR?= MYDTRW5ITVJ?
CAL-51 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DFbGlEPTB;NEOuOVYxPSEQvF2= MoG2V2FPT0WU
RH-18 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:wVGlEPTB;NEOuPFA2KM7:TR?= M4CwRnNCVkeHUh?=
EC-GI-10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLwepBbUUN3ME20N{45OzR5IN88US=> MWPTRW5ITVJ?
HSC-2 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR2LkCwPUDPxE1? MULTRW5ITVJ?
ML-2 NFvhb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnSTWM2OD12NT6yOlIyKM7:TR?= M2TNbnNCVkeHUh?=
KNS-81-FD Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO5OYxtUUN3ME20OU44OzZ3IN88US=> MXfTRW5ITVJ?
NB6 NFT1NJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnZeWJOUUN3ME20Ok4yOTFizszN MYDTRW5ITVJ?
MCF7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i5N2lEPTB;NE[uOVU{OyEQvF2= MWXTRW5ITVJ?
P30-OHK NF\oXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\2VWlEPTB;NE[uPFEyPyEQvF2= NEjUVVZUSU6JRWK=
BPH-1 NIjqd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC5TWM2OD12Nj65PFA2KM7:TR?= NIfaPZdUSU6JRWK=
U251 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR4Lkm5OEDPxE1? MUTTRW5ITVJ?
MKN1 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL5TphKSzVyPUS3MlUyOzdizszN NVy3U49QW0GQR1XS
A431 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGzTWM2OD12Nz64N|M5KM7:TR?= MoLkV2FPT0WU
C8166 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXRTWM2OD12OT6yNFM6KM7:TR?= NWDISGd2W0GQR1XS
HEL M4Dl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETIdGJKSzVyPUS5MlQxPjRizszN M{fVTXNCVkeHUh?=
RMG-I MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTR7LkS0OFQh|ryP MmjtV2FPT0WU
CAL-72 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT4OYlWUUN3ME20PU43ODd3IN88US=> NX34ZoRnW0GQR1XS
SW962 NGXOcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR7LkmzN|Ih|ryP NELTc4tUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

- Collapse

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

- Collapse
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736
Smiles CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=N[NH]3)\C=C\C4=CC=CC=N4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04337970 Recruiting Drug: Talazoparib|Drug: Axitinib Kidney Cancer|Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center April 6 2020 Phase 1|Phase 2
NCT04033991 Active not recruiting Drug: Sunitinib|Drug: Axitinib Carcinoma|Renal Cell Pfizer September 27 2019 --
NCT03472560 Active not recruiting Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Non-Small Cell Lung Cancer|Urothelial Cancer Pfizer May 2 2018 Phase 2
NCT03538717 Completed -- Carcinoma Renal Cell Pfizer April 19 2018 --
NCT03592199 Active not recruiting Drug: Sunitinib Clear Cell Renal Cell Carcinoma Instituto do Cancer do Estado de São Paulo|Pfizer December 11 2017 Phase 2
NCT03289533 Completed Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Carcinoma Hepatocellular Pfizer September 8 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID